Innovative Biologics Expected Biologic Drug Approvals in 2026 DIHEXA PEPTIDE 10MG VIAL UMBRELLA Labs The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Dihexa Research Peptide Protocols: Reconstitution & Storage FDA approval awaited this month . : r biotech_stocks